Introduction {#sec1_1}
============

Obstruction of the portal vein and its tributaries is capable of leading to serious adverse short- and/or long-term events in the affected patients. The tributary portal venous system is anatomically in close proximity (fig. [1](#F1){ref-type="fig"}) \[[@B1]\]; nevertheless, the different sites and the heterogeneous causes of venous obstruction make the possible resulting complications clinically difficult and complicated to treat \[[@B2],[@B3],[@B4]\]. While the occlusion of the extrahepatic portal and splenic vein can provoke complications mainly related to portal hypertension \[[@B1],[@B2],[@B3]\], the mesenteric vein obstruction shows a high rate of complications and mortality due to intestinal infarction \[[@B1],[@B5]\].

The occurrence of this condition is probably underestimated given the fact that the clinical appearance can vary from asymptomatic patients incidentally diagnosed to patients with severe complications \[[@B1],[@B3],[@B6]\]. The technical evolution and the increasing use and availability of appropriate diagnostic tools have profoundly changed the epidemiology of portal vein thrombosis (PVT): from four cases per one million people in 1991 based on hospital registry data \[[@B7]\] this incidence has increased to over 1% in consecutive autopsy series \[[@B6]\] and to 1.74% in computed tomography (CT) analyses in 2012 \[[@B8]\].

From a pathophysiological point of view, PVT is a consequence of the so-called 'Virchow\'s triad', which comprises venous stasis, endothelial injury, and hypercoagulopathy \[[@B2]\]. For this reason, the underlying cause of PVT includes malignancy, chronic liver diseases, local inflammatory processes, systemic disorders including myeloproliferative disorders, and thrombophilia. In a high percentage of patients two or more risk factors are present \[[@B2],[@B4],[@B9]\]. This article summarizes our current knowledge about etiology, risk factors, and complications of this heterogeneous condition in adults. The diagnostic procedures and therapeutic management are discussed elsewhere within this special issue.

Etiological Facts and Risk Factors {#sec1_2}
==================================

In population studies, the cohort of patients with occlusion in the portal tributary system can be divided into three similarly large subcohorts of major etiologies: i) malignant thrombosis mainly due to gastrointestinal, hepatobiliary, or pancreatic cancer, ii) chronic liver diseases, especially liver cirrhosis with portal hypertension, and iii) non-malignant, non-cirrhotic PVT \[[@B1],[@B2],[@B3],[@B6]\]. While the underlying disease determines the natural history and outcome of patients in the case of malignant thrombosis, the two other groups of patients are characterized by an outcome influenced by PVT \[[@B2],[@B10]\]. Furthermore, non-malignant, non-cirrhotic PVT has often been described as an entity of its own, leading to non-cirrhotic portal hypertension, which represents more of a consequence than a complication of another disease \[[@B4]\]. For this reason, the three large etiologic categories are described separately in the following.

Malignant Portal Vein Thrombosis {#sec2_1}
--------------------------------

In general, malignant PVT is associated with the progression of a malignant disease. A thrombosis in the portal system defines vascular invasion of the malignant entity and thereby the spreading to the blood system. Data are scarce on this etiology regarding splanchnic thrombosis; however, primary hepatobiliary cancer, metastatic cancer, and secondary malignancy of the hepatobiliary region can be distinguished \[[@B1],[@B5],[@B6]\]. In a large retrospective study including 23,796 consecutive autopsies (84% of all in-hospital deaths) in the Malmö city population \[[@B6]\], the majority of thromboses occurred due to secondary malignancies of the hepatobiliary region (table [1](#T1){ref-type="table"}). In contrast, detailed statistics revealed that PVT was present in 14.3% of the patients with primary hepatic cancer and concomitant cirrhosis as well as in 11.5% of the patients with pancreatic carcinoma (table [2](#T2){ref-type="table"}). Complications of portal hypertension due to PVT, however, were rather low in cancer patients without cirrhosis in this study, e.g. gastrointestinal bleeding occurred in only 14% compared to 59% in cirrhotics without cancer \[[@B6]\]. Despite these findings, this study is limited because of patient selection (only in-hospital deaths). Other reviews and smaller studies have confirmed these data regarding etiology and distribution of malignant thrombosis, though \[[@B2]\].

Cirrhotic Portal Vein Thrombosis {#sec2_2}
--------------------------------

Liver cirrhosis is a causal factor in approximately one third of all patients with PVT \[[@B2],[@B6],[@B11],[@B12],[@B13]\]. In patients with compensated cirrhosis, the prevalence is approximately 1% \[[@B14]\] and, thus, similar to the prevalence reported in the total population \[[@B6],[@B8]\]. The prevalence of PVT rises to 8-25% in patients awaiting liver transplantation \[[@B2],[@B13],[@B15]\] and is diagnosed in 50-70% in explanted cirrhotic livers during liver transplantation \[[@B15],[@B16]\]. Interestingly, in a systematic review of 885 patients who underwent liver transplantation, the prevalence of PVT was 3.6% in primary sclerosing cholangitis, 8% in primary biliary cirrhosis, and 16% in alcoholic and HBV(hepatitis B virus)-induced cirrhosis but amounted to 36% in patients with liver cirrhosis and hepatocellular carcinoma \[[@B2],[@B13],[@B17]\].

Reasons for the high incidence of PVT in advanced cirrhosis might be the simultaneous presence and effect of the three components of the Virchow\'s triad: venous stasis, endothelial injury, and hypercoagulopathy \[[@B2],[@B18]\].

Venous stasis is common in full-blown cirrhosis and seems to be an important predictor for PVT \[[@B19],[@B20],[@B21]\] because fibrotic tissue deposition and dynamic intrahepatic resistance increase and lead to a lower velocity of portal blood flow \[[@B22]\]. Portal venous congestion increases vascular shear stress with consecutive endothelial injury and vascular dysfunction, which is associated with an overproduction of vasodilators (e.g. nitric oxide) and additionally leads to dysfunctional vasoconstrictor pathways \[[@B23]\]. Together, these two mechanisms result in splanchnic vasodilation with hyperperfusion, which in turn aggravates portal hypertension and portal venous congestion. In cirrhotic patients, the risk for PVT increases when portal venous flow velocity falls below 15 cm/s \[[@B12],[@B13],[@B24],[@B25]\].

Additionally, cirrhosis is characterized by a hypercoagulable state despite the fact that the international normalized ratio (INR) in advanced cirrhosis is often increased \[[@B2],[@B18]\]. In cirrhosis, the physiological balance of pro- and anticoagulatory proteins is disturbed. Indeed, not only the synthesis of the procoagulatory proteins is impaired but also the synthesis of anticoagulatory proteins is decreased \[[@B26],[@B27]\]. Thus, the physiological balance of coagulation is easily tilted either towards bleeding or towards thrombosis \[[@B25],[@B26],[@B28]\]. Increased levels of factor VIII (procoagulant), which increase with a rising Child score, combined with lower levels of protein C (anticoagulant) are believed to be responsible for hypercoagulation. This imbalance and especially the exceeding levels of factor VIII explain the increasing incidence of PVT with worsening liver function in cirrhosis \[[@B29]\]\].

Further risk factors for PVT have been suggested and include lower platelet count, recurrent decompensation, previous bleeding episodes, and infections \[[@B2]\]. These factors predispose and facilitate endotoxin flooding into the portal venous system, which is capable of activating the coagulation cascade and may lead to thrombus formation \[[@B30]\]. In contrast, inherited thrombophilias (i.e. G20210A prothrombin mutation, factor V Leiden mutation, TT677 MTHFR gene mutation) play a minor pathogenic role in cirrhotic PVT \[[@B2],[@B18],[@B31]\].

These data, hypotheses, and studies might explain the observation that in 8-16% patients with end-stage liver disease on a waiting list for liver transplantation de novo PVT develops within 12 months of follow-up \[[@B13]\].

Non-Malignant, Non-Cirrhotic Portal Vein Thrombosis {#sec2_3}
---------------------------------------------------

PVT in the absence of malignancy and cirrhosis is mainly due to systemic prothrombogenetic conditions and local factors \[[@B4],[@B32]\] (table [3](#T3){ref-type="table"}). Among these factors, myeloproliferative neoplasias appear as a major cause in 20-50% of the patients with PVT \[[@B10],[@B32]\]. In a meta-analysis of 855 patients with PVT, myeloproliferative neoplasms were present in about 30% of the patients, and JAK2 V617F mutations were found in 28% of the cohort \[[@B9]\]\]. First data on the role of the recently described novel mutation in the calreticulin gene for myeloproliferative neoplasm does not seem to play an important role in patients with PVT \[[@B33]\].

Inherited and acquired thrombophilias (table [3](#T3){ref-type="table"}) appear to play a more important role in patients with Budd-Chiari syndrome than in PVT \[[@B2]\]. However, in almost half of the patients with PVT more than one risk factor or cause was present \[[@B4]\]. Therefore, investigations to identify a prothrombotic risk factor in patients with local causes for the PVT and vice versa are necessary and recommended \[[@B2],[@B4]\].

Clinical Findings and Complications of Portal Vein Thrombosis {#sec1_3}
=============================================================

The site (fig. [1](#F1){ref-type="fig"}), extent (partial or complete), chronicity (acute or chronic), and course (progressive or self-resolving) of thromboses determine their clinical presentation as well as their complications in affected patients \[[@B2]\]. While partial PVT is usually discovered incidentally by routine diagnostics and remains clinically silent, the complete occlusion of the vein (90-100% of the lumen) is associated with abdominal and/or lumbar pain characterized by sudden onset or progressive development over the course of a few days \[[@B18]\]. Acute and complete thrombosis is usually associated with intestinal congestion and occasionally with non-sanguineous diarrhea \[[@B12],[@B34],[@B35]\]. In this case, a diffuse and homogeneous thickening of the intestinal wall may be present in imaging studies \[[@B36]\].

The most feared complication is intestinal infarction with a mortality of 20-60%, leading to extended resections with a high risk of postoperative complications \[[@B4],[@B5],[@B37],[@B38],[@B39],[@B40],[@B41]\]. In contrast to intestinal congestion, infarction often presents with persistent pain, hematochezia, guarding, contracture, ascites, or multiorgan failure with metabolic acidosis \[[@B4]\]. In a usually urgently performed CT scan, the major findings can include hypo- or hyperattenuated wall thickening, dilatations, abnormal or absent wall enhancement, mesenteric stranding, ascites, pneumatosis, and portal venous gas \[[@B4],[@B42]\]. It is important to emphasize that this complication is usually found when the mesenteric veins are involved \[[@B2],[@B4]\]. Interestingly, in a retrospective analysis performed in patients with mesenteric vein thrombosis, a lack of performing CT studies was associated with an increased mortality \[[@B5]\].

Complications due to Portal Hypertension {#sec2_4}
----------------------------------------

The majority of complications of long-standing PVT are due to portal hypertension \[[@B2],[@B4]\]. Collateralization of the portal vein might lead to the development of the so-called portal cavernoma \[[@B4]\]. However, portosystemic shunting can also develop, since these cavernous collaterals may not sufficiently drain the portal blood flow, and portal pressure is not sufficiently decreased. This usually presents as de novo appearance and/or progression of gastric or esophageal varices and may be complicated by bleeding \[[@B4],[@B35],[@B43],[@B44]\]. Bleeding due to PVT occurs about 100 times more often in patients with cirrhosis \[[@B45],[@B46]\]. In comparison, cirrhotic patients with PVT exhibit a 10% higher bleeding rate compared to cirrhotic patients without PVT \[[@B13]\]. Therefore, cirrhotic portal hypertension is a major risk factor for bleeding, and PVT in cirrhotic patients considerably aggravates this problem.

Another but less frequent complication of collateral vessel formation is the pronounced portosystemic shunting in some patients, which leads to subclinical hepatic encephalopathy \[[@B4],[@B35],[@B43],[@B44]\]. Furthermore, the development of collaterals can deform the biliary tree and may thus lead to a so-called portal biliopathy or cholangiopathy \[[@B4],[@B47],[@B48],[@B49]\], which is present in almost all patients although only few develop secondary biliary complications \[[@B49]\].

Complications due to Decompensation of Chronic Liver Disease {#sec2_5}
------------------------------------------------------------

One frequent complication is the recurrence of thrombosis, which can maintain or aggravate a critical clinical situation of the affected patient \[[@B4],[@B35],[@B44]\]. Especially in cirrhotic patients, PVT is a common cause of decompensation \[[@B2],[@B11]\]. In the literature, the hypothesis of hepatic parenchymal extinction as a consequence of microthrombi into the intrahepatic vascular tree with consecutive fibrotic remodeling of liver tissue has been extensively discussed but not conclusively proven in detail to date \[[@B2],[@B11],[@B50],[@B51]\]. Apart from this hypothesis, coagulation activity and progressive liver fibrosis have been shown to be linked to each other \[[@B11]\]. Provocatively speaking, the development of an extrahepatic PVT can be regarded as the natural history of liver cirrhosis \[[@B11]\]. However, cirrhotic patients with an obstruction of the portal venous system show an increased mortality \[[@B52]\]. These patients exhibit a mortality rate similar to patients with a MELD (model for end-stage liver disease) score of 26, even though their laboratory MELD was calculated to be 12 \[[@B52]\]. Furthermore, the posttransplant survival is decreased in patients with PVT \[[@B52],[@B53]\], which appears to be dependent on the extent of the thrombosis \[[@B53]\]. Taken together, PVT must be carefully considered during the diagnostic and therapeutic decision making in cirrhotic patients as it profoundly influences survival.

Conclusions {#sec1_4}
===========

Portal vein occlusion is a clinically relevant disorder which should be rapidly diagnosed and which requires interdisciplinary collaboration in order to prevent or treat invariably ensuing complications. The underlying cause should be investigated, and other causes should be excluded. Multifactorial causes are frequent. Particularly patients with liver cirrhosis require special care with regard to PVT since this is linked to the pathophysiology of the disease and thus influences patient survival.
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![Splanchnic venous thrombus location. Percentages and location of isolated venous segment thrombosis are presented whereas the percentage of multiple vein thrombosis is summarized \[[@B1]\].](vim-0030-0375-g01){#F1}

###### 

Prevalence of patients with PVT (n = 254) of the conditions known to be major causes \[[@B6]\]

  Patient category                                      n (%) of PVT patients   n (%) within risk category
  ----------------------------------------------------- ----------------------- ----------------------------
  Cirrhosis^a^                                          72 (28)                 
   With primary hepatic cancer                                                  26 (36)
   Without primary hepatic cancer                                               46 (64)
  Primary hepatobiliary cancer^a^                       59 (23)                 
   Hepatic carcinoma                                                            38 (64)
   Biliary/gall bladder carcinoma                                               21 (36)
  Secondary malignancy of the hepatobiliary region^a^   111 (44)                
   Pancreatic carcinoma                                                         47 (42)
   Gastric carcinoma                                                            20 (18)
   Colorectal carcinoma                                                         11 (10)
   Lung cancer                                                                  7 (6)
   Malignant lymphoma                                                           5 (4)
   Other primary cancer                                                         21 (19)^a^
  Myeloproliferative disorders^a^                       7 (3)                   
  Major abdominal infection/inflammation^a^             25 (10)                 
  No cause identified                                   36 (14)                 

Categories are not mutually exclusive.

###### 

Prevalence and relative risk (OR) of PVT in relation to disease condition with major risk of PVT \[[@B6]\]

  Patient category                                   n (%)          PVT (%)     OR (95% CI)
  -------------------------------------------------- -------------- ----------- -------------------
  Cirrhosis                                          1,193 (5.0)    72 (6.0)    7.9 (6.0--10.5)
   With primary hepatic cancer                       182            26 (14.3)   17.1 (11.1--26.4)
   Without primary hepatic cancer                    1,011          46 (4.5)    5.2 (3.7--7.2)
  Primary hepatobiliary cancer                       698 (2.9)      59 (8.5)    10.8 (8.0--14.7)
   Hepatic carcinoma                                 392            38 (9.7)    11.5 (8.0--16.5)
   With cirrhosis                                    182            26 (14.3)   17.1 (11.1--26.4)
   Without cirrhosis                                 210            12 (5.7)    5.8 (3.2--10.6)
  Biliary/gall bladder carcinoma                     313            21 (6.7)    7.2 (4.5--11.4)
  Secondary malignancy of the hepatobiliary region   3,446 (14.5)   113 (3.3)   4.9 (3.8--6.2)
   Pancreatic carcinoma                              312            36 (11.5)   13.9 (9.6--20.2)
   Gastric carcinoma                                 316            18 (5.6)    5.9 (3.6--9.7)
   Colorectal carcinoma                              637            13 (2.0)    2.0 (1.1--3.5)
  Myeloproliferative disorders                       231 (1.0)      7 (2.0)     3.0 (1.4--6.3)
  All patients                                       23,796         254 (1.0)   

OR = Odds ratio; CI = confidence interval.

###### 

Inherited and acquired risk factors for acute PVT \[[@B4], [@B32]\]

  Underlying disorder                   n tested   positive
  ------------------------------------- ---------- ----------
  Myeloproliferative neoplasm           102        21
  JAK2-positive                         82         16
  Antiphospholipid syndrome             90         8
  Paroxysmal nocturnal hemoglobinuria   39         0
  Factor V Leiden                       94         3
  Factor II mutation                    98         14
  Protein C deficiency                  86         1
  Protein S deficiency                  85         5
  Antithrombin deficiency               89         2
  Hyperhomocysteinemia                  69         11
  Recent pregnancy                      50         1
  Recent oral contraceptive use         50         44
  Systemic disease                      101        4
  More than one risk factor^a^          102        52
  Local factor^b^                       102        21

Including connective tissue disease, inflammatory bowel disease, Behcet\'s disease, HIV infection.

Acute pancreatitis, intra-abdominal focus of infection, or abdominal trauma.
